What this means
In a trial of 84 adults, semaglutide was linked to slower aging scores on several blood-based measures. This was an extra analysis not planned at the start, so it cannot prove the drug slows aging.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- 84 adults with HIV-associated lipohypertrophy in a randomized trial
- Kind of research
- A clinical trial in people
The science
- Original title
- Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.
- Authors
- Corley MJ, Dwaraka VB, Pang AP et al.
- Journal
- Nature communications
- Published
- May 19, 2026
- Study type
- Clinical trial · in humans
- PMID
- 42156721 ↗
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). The parent trial's primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic aging was not pre-specified. To address this gap, we profiled peripheral-blood DNA methylation (DNAm) at baseline and week 32 to assess semaglutide versus placebo on first-, second-, and third-generation epigenetic aging measures. In adjusted analyses, semaglutide reduced epigenetic aging across multiple second- and third-generation clocks, including PhenoAge ( - 4.9 years/year, p = 0.004), PCGrimAge ( - 3.1, p = 0.007), GrimAge V2 ( - 2.3, p = 0.009), OMICmAge ( - 2.2, p = 0.009), RetroAge ( - 2.2, p = 0.030), and DunedinPACE ( - 0.09 units, 9% slower, p = 0.01). Systems-based clocks showed parallel reductions in inflammation, brain, and heart aging measures. The post hoc design, modest sample size, HIV-specific cohort, and 32-week follow-up limit generalizability. Prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics.
Corley MJ, Dwaraka VB, Pang AP et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nature communications. 2026. doi:10.1038/s41467-026-72861-3. PMID: 42156721. https://pubmed.ncbi.nlm.nih.gov/42156721/
See all research on GLP-1 drugs →